The Fly | NRXP

Over a week ago

NRx Pharmaceuticals issues response to Kadima statements

NRXP

Jun 25, 4:13 PM

Psychedelic: Definium soars on study results for LSD-based depression treatment

Jun 25, 10:14 AM

Kadima Neuropsychiatry Institute alleges NRx breached contract

NRXP

Jun 24, 1:22 PM

ZETA announces treatment of first patient with Zeta TMS Navigation System

NRXP

Jun 23, 11:08 AM

NRx Pharmaceuticals announces FDA grant of expanded access protocol for NRX-101

NRXP

Jun 22, 7:14 AM

Psychedelic: Optimi Health completes psilocybin export to the UK

Jun 11, 10:15 AM

NRx Pharmaceuticals 5.7M share Spot Secondary priced at $3.50

NRXP

Jun 3, 8:45 AM

NRx Pharmaceuticals announces common stock offering, no amount given

NRXP

Jun 2, 4:03 PM

Psychedelic: Optimi Health advances natural psilocybin extract

May 28, 10:19 AM

Psychedelic: Enveric, NRx, Bright Minds report quarterly earnings

May 21, 11:26 AM

Psychedelic: Compass Pathways, AtaiBeckley, GH Research report earnings

May 14, 11:09 AM

NRx Pharmaceuticals initiated with bullish view at Lucid Capital, here's why

NRXP

May 13, 6:08 AM

Psychedelic: Jefferies initiates Compass Pathways with a Buy rating

May 7, 10:26 AM

NRx Pharmaceuticals gets FDA clearance to initiate NRX-101 trial

NRXP

May 7, 9:54 AM

NRx Pharmaceuticals receives first commercial manufacturing order for ketamine

NRXP

May 5, 9:28 AM

NRx Pharmaceuticals gets FDA feedback on ketamine program

NRXP

Apr 22, 7:25 AM

White House shift on psychedelics positive for NRx, says D. Boral

NRXP

Apr 20, 9:02 AM

NRx Pharmaceuticals welcomes the newly-signed Executive Order

NRXP

Apr 20, 7:11 AM

Psychedelic: Clearmind's CMND-100 meets primary endpoint in trial

Apr 16, 11:20 AM

NRx Pharmaceuticals announces incorporation of NRx Defense Systems

NRXP

Apr 16, 10:49 AM

NRx Pharmaceuticals appoints Glenn Tyson chief commercial officer

NRXP

Apr 13, 7:05 AM

Psychedelic: AtaiBeckley reports publication of BPL-003 study results

Apr 9, 10:57 AM

NRx Pharmaceuticals announces FDA labeling alignment for ketamine product

NRXP

Apr 6, 7:06 AM

Psychedelic: Clearmind completes treatment, follow-up for CMND-100 trial

Apr 2, 9:50 AM

Psychedelic: Compass Pathways, NRx Pharma report earnings results

Mar 26, 10:57 AM

Addressing High Unmet Medical Needs: Focus on severe psychiatric conditions like suicidal bipolar depression and PTSD, where existing treatments are often inadequate, offering significant therapeutic potential.

Novel Mechanism of Action in CNS Disorders: Leveraging NMDA receptor modulation with candidates like NRX-101, which provides a differentiated approach for difficult-to-treat mental health conditions.

Breakthrough Therapy Designation for Key Candidate: NRX-101 for suicidal bipolar depression has received this prestigious FDA designation, potentially accelerating its development and review process.

Clinical Trial Failures: NRXP's drug candidates may not achieve primary or secondary endpoints in clinical trials, or may show unacceptable safety profiles, leading to a halt in development and significant financial loss.

Regulatory Approval Delays or Denials: NRXP may fail to obtain necessary regulatory approvals from agencies like the FDA or EMA for its drug candidates, or approvals may be significantly delayed, preventing or postponing market entry.

Insufficient Funding and Liquidity: NRXP operates at a loss and requires substantial additional capital to fund its research, clinical trials, and commercialization efforts; failure to secure this funding could jeopardize its operations.